Lake Bleu Capital is a multi-billion dollar asset management platform based in Hong Kong and Shanghai. See sector focus, stage focus and contact routes.
Lake Bleu Capital is a multi-billion dollar asset management platform based in Hong Kong and Shanghai, established in 2019 to specialize in healthcare, pharmaceutical, and technology innovation sectors. The firm executes a long-term investment thesis focused on mid-to-late-stage opportunities across the entire healthcare value chain in Asia, with a primary concentration on Greater China. It manages strategies through both public and private equity, targeting subsectors including biopharmaceuticals, medical devices, and healthcare services. While specific check sizes and lead/follow behavior are not publicly detailed, the firm has led significant rounds, such as the over $100 million financing for RemeGen (荣昌生物) in 2020 alongside Lilly Asia Ventures. Notable portfolio companies include RemeGen, a biopharmaceutical company, and the firm invests broadly across the Asian healthcare ecosystem. Lake Bleu Capital adheres to a value-creating strategy driven by rigorous bottom-up fundamental research to identify high-growth potential companies. The firm holds Hong Kong SFC Type 9 (asset management) licensing and serves only professional investors, dist
StartupFundraising tracks this firm record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in Hong Kong.
Investors like Lake Bleu Capital · Full investor directory · Investor access · Company funding database